Stock comparison
CorMedix
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CRMD
CorMedix
Market cap
$626.05M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CRMD | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 75B | IDXX |
| Benjamin Graham | 38D | 80A | IDXX |
| Philip Fisher | 64C | 75B | IDXX |
| Peter Lynch | 64C | 71B | IDXX |
| Joel Greenblatt | 48D | 83C | IDXX |
| Charlie Munger | 67D | 87A | IDXX |
| Terry Smith | 71B | 84A | IDXX |
Side-by-side metrics
| Metric | CRMD | IDXX |
|---|---|---|
| Market cap | $626.05M | $44.12B |
| P/E (TTM) | 3.3x | 39.0x |
| EV/EBIT | 3.7x | 31.6x |
| ROIC (TTM) | 27.59% | 40.66% |
| Gross margin | 85.83% | 62.05% |
| Net margin | 45.25% | 24.63% |
| Revenue CAGR 5y | 5.36% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.3x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CRMD leads on
- Revenue CAGR 5y5.36%vs 7.56%+99%
- P/E (TTM)3.3xvs 39.0x+92%
- EV/EBIT3.7xvs 31.6x+88%
- Debt / Equity0.3xvs 0.7x+52%
IDXX leads on
- Market cap$44.12Bvs $626.05M+99%
- ROIC (TTM)40.66%vs 27.59%+32%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.